KITE-753

Phase 1Small molecule

Gilead

KITE-753 is one of 83 small molecule programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Relapsed And/or Refractory B-Cell LymphomaRecruiting

B-Cell Acute Lymphoblastic LeukemiaNot yet recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Relapsed And/or Refractory B-Cell LymphomaPreclinical

Recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 1

Not yet recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Oncaspar

SServier

Preclinical

15 3

Norvir

AbbVie

Preclinical

1 4

Tafasitamab

Incyte

Preclinical

7 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

PEG-Intron

Merck & Co.

Preclinical

1 10

KITE-753

Gilead

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

PreclinicalRecruiting

Relapsed And/or Refractory B-Cell Lymphoma

NCT04989803

Q2 2031

Phase 1Not yet recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT07674823

Phase 3Not yet recruiting

Lymphoma

NCT07479797

Clinical

Trials by Indication[1]

Lymphoma1 trial

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Not yet recruiting· Gilead logo

Gilead·Phase 3·NCT07479797·550 enrolled

Long-term Follow-up1 trial

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Enrolling by invitation· Gilead logo

Gilead··NCT05041309·1,000 enrolled

B-cell acute lymphoblastic leukemia1 trial

A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07674823·18 enrolled

Relapsed and/or Refractory B-cell Lymphoma1 trial

A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma

Recruiting· Gilead logo

Gilead·Preclinical·NCT04989803·247 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for KITE-753. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KITE-753 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KITE-753. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Gilead

KITE-753

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Q2 2031

Trials by Indication[1]

Lymphoma1 trial

Long-term Follow-up1 trial

B-cell acute lymphoblastic leukemia1 trial

Relapsed and/or Refractory B-cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News